文献速递真实世界研究与卫生经济流行病学与生物统计

利用注册数据桥接类风湿关节炎一线与二线生物制剂治疗的不连通网络:目标试验模拟的贝叶斯证据合成

Bridging disconnected networks of first and second lines of biologic therapies in rheumatoid arthritis with registry data: bayesian evidence synthesis with target trial emulation.
PubMed 文献 · J Clin Epidemiol · 2022-07-16

本研究利用英国风湿病学会类风湿关节炎生物制剂注册数据,通过模拟目标试验估计各线治疗效应,并以此补充随机对照试验证据,构建一线与二线治疗的双变量网络荟萃分析。结果显示,与单变量网络荟萃分析相比,双变量网络荟萃分析降低了二线治疗疗效估计的不确定性,并可预测二线随机对照试验未评估的治疗效应。

要点

  • 利用注册数据模拟目标试验,可估计一线与二线生物制剂的治疗效应。
  • 双变量网络荟萃分析较单变量网络荟萃分析降低二线治疗疗效估计的不确定性。
  • 该方法可预测二线随机对照试验未评估的治疗效应。

核心结论

  • 双变量网络荟萃分析可提供一线和二线所有治疗的疗效估计,包括数据中不存在的二线预测效应。

研究设计与样本

  • 研究使用英国风湿病学会类风湿关节炎生物制剂注册数据,通过模拟治疗序列的目标试验估计各线治疗效应。
  • 目标试验的治疗效应估计用于构建一线与二线治疗的双变量网络荟萃分析。

主要发现

  • 汇总数据来自21项生物制剂治疗试验,其中2项为二线治疗,以及6项模拟目标试验的结果,涵盖两个治疗线。
  • 与单变量网络荟萃分析相比,双变量网络荟萃分析降低了二线治疗疗效估计的不确定性。
  • 双变量网络荟萃分析可预测二线随机对照试验未评估的治疗效应。

关键数值与推荐

  • 原文未报告具体的疗效数值、置信区间或P值。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aim to use real-world data in evidence synthesis to optimize an evidence base for the effectiveness of biologic therapies in rheumatoid arthritis to allow for evidence on first-line therapies to inform second-line effectiveness estimates. STUDY DESIGN AND SETTING: We use data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis to supplement randomized controlled trials evidence obtained from the literature, by emulating target trials of treatment sequences to estimate treatment effects in each line of therapy. Treatment effects estimates from the target trials inform a bivariate network meta-analysis (NMA) of first-line and second-line treatments. RESULTS: Summary data were obtained from 21 trials of biologic therapies including two for second-line treatment and results from six emulated target trials of both treatment lines. Bivariate NMA resulted in a decrease in uncertainty around the effectiveness estimates of the second-line therapies, when compared to the results of univariate NMA, and allowed for predictions of treatment effects not evaluated in second-line randomized controlled trials. CONCLUSION: Bivariate NMA provides effectiveness estimates for all treatments in first and second line, including predicted effects in second line where these estimates did not exist in the data. This novel methodology may have further applications; for example, for bridging networks of trials in children and adults.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Bujkiewicz S, Singh J, Wheaton L, et al. Bridging disconnected networks of first and second lines of biologic therapies in rheumatoid arthritis with registry data: bayesian evidence synthesis with target trial emulation. J Clin Epidemiol. 2022. PMID: 35850425. doi:10.1016/j.jclinepi.2022.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。